Navigation Links
endpoint Launches PULSE 2.0 Allowing Clinical Research Teams to Save Additional Time and Money By Rapidly Deploying Studies With Custom Reporting
Date:10/19/2010

SAN FRANCISCO, Oct. 19 /PRNewswire/ -- endpoint Clinical (www.endpointclinical.com), a leader in Integrated Response Technology (IRT) development, today announced the release of PULSE 2.0™. endpoint PULSE is a proprietary platform that enables the configuration of fully validated, custom IRT systems for clinical trials in a fraction of the time required by traditional development. New in PULSE 2.0 is the ability for project managers to create and manage client-specific templates, ensuring that every study endpoint develops automatically contains the client's preferred configurations. PULSE 2.0 also offers enhanced reports and administrative functionality, with a focus on improved control over clinical supplies.

endpoint's PULSE configurable architecture meets Clinical Program Managers' demands for making mid-study changes quickly and easily. endpoint's PULSE platform combines IRT capabilities with pre-validated modules allowing clinical trials to move ahead at a more rapid rate due to project managers having access to the configurable design elements rather than relying on custom development for each change.

"Since launching PULSE in February, we've been compiling a long list of new features and functionality," said Jonathan Dole, co-founder and CEO, endpoint. "PULSE 2.0 is a blend of features our customers are asking for and new tools that enable us to deliver an even more robust IRT system in the same timeframe to which our customers are becoming accustomed."

About endpoint

endpoint is an innovative company dedicated to the development of the leading technology platforms for the life sciences industry. endpoint's founding team has been developing IRT systems for clinical trials since 1998 and have deployed systems to small, medium and large pharma for domestic and global studies with experience across a broad range of therapeutic areas and global implementations. For more information, visit endpoint at www.endpointclinical.com.


'/>"/>
SOURCE endpoint
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Phase 3 Trial of Nexavar in First-Line Advanced Non-Small Cell Lung Cancer Does Not Meet Primary Endpoint of Overall Survival
2. Pivotal Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint in Study of Patients With Advanced Pancreatic Neuroendocrine Tumors
3. TaiGen Announces Nemonoxacin (TG-873870) Once-A-Day Oral Dosing in Diabetic Foot Infection Met Primary Endpoints
4. LEO Pharmas PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition
5. Poniard Pharmaceuticals Announces Phase 2 Trial of Picoplatin in Metastatic Colorectal Cancer Meets Primary Endpoint and Study Objectives
6. American Heart Association Late-Breaking Clinical Trial Report: New Blood Thinner for Angioplasty Patients Not Superior for Primary Endpoint, but Did Reduce Death and Stent Thrombosis
7. Investigational Sublingual Allergy Immunotherapy Tablet Meets Primary Endpoint in a Study of Adult Subjects With a History of Grass Pollen Allergies
8. Novartis drug Tasigna(R) meets primary endpoint in pivotal trial against Gleevec(R) as first-line treatment in chronic myeloid leukemia patients
9. Intercept Pharmaceuticals FXR Agonist INT-747 Meets Primary Endpoint in a Phase II Clinical Trial in Type 2 Diabetic Patients with Nonalcoholic Fatty Liver Disease
10. Dirucotide Does Not Meet Primary Endpoint in Phase III MAESTRO-01 Trial in Secondary Progressive Multiple Sclerosis
11. R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... S.C. , July 10, 2017  BDI ... purchasing and patient support services organization serving specialty ... today the launch of four significant, value-added member ... market insights, better manage reimbursement and improve access ... and factor therapies. ...
(Date:7/6/2017)... division of Diplomat Specialty Infusion Group, is celebrating a decade of empowering ... celebrate its anniversary, ThriveRx recently launched a redesigned website at thriverx.diplomat.is ... to create the best user experience for consumers and health care professionals. ... Diplomat Pharmacy ... "We,ve made several great strides throughout the past 10 years," ...
(Date:7/5/2017)... , July 5, 2017 Pace Analytical, a company of over 2,000 ... that they have acquired ESC Lab Sciences, further solidifying their position as the ... States . ... Vanderboom- President and CEO of Pace Analytical ... Lab Sciences out of Mt Juliet, TN , enhances Pace ...
Breaking Medicine Technology:
(Date:7/24/2017)... ... July 24, 2017 , ... Clinical Quality Assurance:, Roles and ... 22-23, 2017 – Arlington, VA, http://www.fdanews.com/cqa , Early bird pricing for ... growing demands to track and report adverse events place even greater pressure on ...
(Date:7/24/2017)... Province (PRWEB) , ... July 24, 2017 , ... ... Medicine's "Chinese Medicine Clinical Vitiligo Hospital" was set up, and the awarding ceremony ... of traditional Chinese medicine, the head of the army's health system, and national ...
(Date:7/24/2017)... ... 2017 , ... “The Perfect Gift”: a customizable and interactive Bible study guide for children. “The ... born-again Christian. She has always accepted Christ as her Savior, yet never studied His ... the Spirit when she wrote this book to her children, so they would know the ...
(Date:7/24/2017)... ... ... “A Short Walk to the Mailbox”: a remarkable memoir of an unconventional ... Ed Clark. Ed Clark is a church music director and choral conductor. ... music and worship leader for over fifty years. He has a master’s degree ...
(Date:7/24/2017)... ... 24, 2017 , ... The Center for Addiction Recovery Training ... host a second Multiple Pathways of Recovery Conference on October 23-26, 2017. This ... from CCAR’s foundational principle – a belief in multiple pathways of recovery, aims ...
Breaking Medicine News(10 mins):